GEN Exclusives

More »

GEN News Highlights

More »
Apr 15, 2008

Roche Pays $160M for Piramed Gaining Early Oncology and Inflammatory Disease Programs

  • Roche has decided to buy Piramed for $160 million to expand its early-stage cancer pipeline. Roche will pay an additional $15 million as a milestone fee upon the start of a Phase II trial for Piramed’s oncology program. Roche expects to close the transaction during the second quarter.

    Piramed’s R&D focus has been on therapeutics targeting PI3-kinase (PI3K). Piramed has a program targeting PI3K-delta for inflammatory diseases in the preclinical stage and is also working on PI3K-alpha for oncology indications. The oncology program has a Phase I compound, which is being partnered by Genentech, in whom Roche has a majority ownership interest.

    Roche has been busy picking up companies to beef up different segments of its franchise. Most recently, Roche finalized a deal to take over Ventana Medical Systems for $3.4 billion to pad its diagnostics interest. Last year, Roche spent around $1.08 billion to acquire NimbleGen, BioVeris, Therapeutic Human Polyclonals, and 454 Life Sciences.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?